Cargando…

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process

A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murillo-Fernández, Mac Arturo, Montero-Zeledón, Ernesto, Abdala-Saiz, Ariadna, Vega-Baudrit, José Roberto, Araya-Sibaja, Andrea Mariela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875139/ https://www.ncbi.nlm.nih.gov/pubmed/35214156 http://dx.doi.org/10.3390/pharmaceutics14020424

Ejemplares similares

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
por: Greathouse, Mark
Publicado: (2006)

Spectrophotometric Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in Tablet
por: Rote, A. R., et al.
Publicado: (2010)

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
por: Punzi, Henry A
Publicado: (2011)

Derivative and Q-analysis Spectrophotometric Methods for Estimation of Hydrochlorothiazide and Olmesartan Medoxomil in Tablets
por: Bhusari, K. P., et al.
Publicado: (2009)

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2015)

Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2016)

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis
por: Kumar, Lakshya, et al.
Publicado: (2023)

Hydrochlorothiazide/ibuprofen/olmesartan medoxomil: Drug misuse and acute tubular injury: case report
Publicado: (2021)

RP-LC and HPTLC Methods for the Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Combined Tablet Dosage Forms
por: Bari, P. D., et al.
Publicado: (2009)

Central Composite Design for Validation of HPTLC Method for Simultaneous Estimation of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Tablets
por: Solanki, Trupti B., et al.
Publicado: (2014)

Application of a Stability-Indicating HPTLC Method for Simultaneous Quantitative Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Pharmaceutical Dosage Forms
por: Ilango, Kaliappan, et al.
Publicado: (2013)

Olmesartan medoxomil for the treatment of hypertension in children and adolescents
por: Tocci, Giuliano, et al.
Publicado: (2011)

Olmesartan medoxomil: Allergic reaction: case report
Publicado: (2022)

Olmesartan medoxomil: current status of its use in monotherapy
por: Brunner, Hans R
Publicado: (2006)

Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement
por: Thakkar, Hetal Paresh, et al.
Publicado: (2011)

Small bowel enteropathy associated with olmesartan medoxomil treatment
por: Galanopoulos, Michail, et al.
Publicado: (2017)

Olmesartan-medoxomil: Sprue-like enteropathy: case report
Publicado: (2021)

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension
por: Cushman, William C., et al.
Publicado: (2018)

Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil
por: Song, SaeHeum, et al.
Publicado: (2016)

Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies
por: Patel, Jaydeep, et al.
Publicado: (2011)

Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy
por: Punzi, Henry, et al.
Publicado: (2012)

Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial
por: Oparil, S, et al.
Publicado: (2010)

A novel nano-formulation of olmesartan medoxomil with improved delivery and efficacy in the treatment of indomethacin-induced duodenitis in rats
por: Murad, H.A., et al.
Publicado: (2023)

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
por: Ferrario, Carlos
Publicado: (2009)

Simultaneous Estimation of Amlodipine Besilate and Olmesartan Medoxomil in Pharmaceutical Dosage Form
por: Wankhede, S. B., et al.
Publicado: (2009)

Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine
por: Ishizuka, Tomoko, et al.
Publicado: (2010)

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments
por: Almutairy, Bjad K., et al.
Publicado: (2021)

Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study
por: Martinez-Martin, F J, et al.
Publicado: (2011)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
por: Mason, R Preston
Publicado: (2011)

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
por: Chrysant, S G, et al.
Publicado: (2010)

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
por: El-Dahmy, Rania Moataz, et al.
Publicado: (2023)

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil
por: Hanumantha Rao, Bommena, et al.
Publicado: (2015)

Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology
por: Attari, Zenab, et al.
Publicado: (2016)

Preparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability Improvement
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation
por: Nasr, Ali, et al.
Publicado: (2016)

Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis
por: Roth, Eli M., et al.
Publicado: (2013)

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals
por: Basile, Jan
Publicado: (2010)

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
por: Barrios, Vivencio, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_982415ls02v357g73fbs1p9p3i